ImmuCell is a Maine-based animal health company that has spent the last eighteen months executing a clean strategic contraction. The Re-Tain mastitis program is parked, the former Re-Tain plant is being rebuilt as a colostrum processing facility, and a single product line, First Defense, now accounts for nearly the entire revenue base.
The second-quarter print shows why the pivot matters. A one-time settlement from Norbrook Laboratories lifted net income sharply, while the underlying gross margin compressed on higher costs of goods sold. The settlement amount and the margin move are both large enough to define the quarter. Cash ended the half at a level roughly equal to total debt, which is a clean balance sheet but not a growth war chest.
The question for the next two quarters is whether the rebuild holds the margin line once the settlement rolls off and the fourth-quarter earnings arrive without the one-time windfall.